Tenaya Therapeutics (TNYA) Price to Sales (2026)
Tenaya Therapeutics (TNYA) posted Price to Sales of 149.49 for Q2 2026, down 77.61% on a QoQ basis from 667.78 in Q1 2026.
Powered by 
Analysis
Tenaya Therapeutics (TNYA) Price to Sales (2026) Analysis & Trends
Tenaya Therapeutics has reported Price to Sales for 1 years, with the latest figure at 149.49 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.37 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - |
| 3 | Iovance Biotherapeutics | 3.66 Bn | 3.36 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn |
| 5 | uniQure | 3.00 Bn | 3.00 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - |
| 7 | Precigen | 2.37 Bn | 2.37 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.17 Bn | 1.37 Bn | 251.87 Mn |
| 9 | Vericel | 1.95 Bn | 1.79 Bn | 56.40 Mn |
| 10 | Tenaya Therapeutics | 141.42 Mn | 141.42 Mn | - |